Clinical Trial Update: Long-Term Follow-Up Safety Study of Subjects Treated with SynKIR-110 in Cancer Studies

View source ↗

Summary

The long-term follow-up safety study of SynKIR-110 in cancer studies has been withdrawn from clinical trials records.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• SynKIR-110 (SynKIR-110)

Snippet

Sponsor: Verismo Therapeutics | Conditions: Cancer | Status: WITHDRAWN